We noticed you are on our US page. Want to switch regions? Choose from the options:
We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Intensity Modulated Radiation Therapy followed by Cesium‐131 Brachytherapy for Intermediate and High Risk Localized Prostate Cancer.